What kind of a presence will Daiichi Sankyo have on the Ranbaxy board?
After the deal is complete, the Ranbaxy board will be reconstituted and reduce from 15 (members) to 10. Daiichi Sankyo will have six members on the board and there will be four people from my side. I’ll be part of their global management team. What assures you of your position in the company, given that you will have no equity stake? Is there a five-year period for you being in Ranbaxy? There is a very clear understanding (with Daiichi Sankyo) of how the business will be run, of the purpose and rationale behind the deal. There is a common vision for Daiichi-Ranbaxy between their CEO and me. At the same point of time, there was a clear imperative from their side when they said: “We don’t want Ranbaxy without you. We want it, if and only if you are going to continue to lead the company.” They would like to have me as long as possible. There is a simple reason behind the five-year time frame that we have spoken of. As per Indian regulations, any executive director needs to go for sharehol
